United States — Food and Drug Administration & Reed Kathrein
8 shared events · Importance 3 · Last updated Aug 20, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States — Food and Drug Administration: The FDA issued a warning letter to Medline citing manufacturing violations, which triggered the investigation and market decline.
Reed Kathrein: Reed Kathrein is the HBSS partner leading the investigation, acting as a key figure in the shareholder probe.
Jul 01, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA placed a full clinical hold on ARD-101's IND, halting all ongoing studies. This regulatory action is central to the lawsuit and has severely impacted Aardvark's operations and stock price.
Reed Kathrein: Reed Kathrein is the Hagens Berman partner leading the investigation of the claims. He is involved in representing investors and whistleblowers.
Aug 14, 2026 · 23 articles
Regulatory
United States — Food and Drug Administration: Regulator whose briefing documents and advisory committee vote triggered the stock collapse and legal actions.
Reed Kathrein: Partner at Hagens Berman leading the investigation.
Jul 27, 2026 · 293 articles
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration issued a warning letter to ImmunityBio regarding misleading efficacy claims made by Patrick Soon-Shiong about Anktiva, which triggered the stock price drop and subsequent lawsuits.
Reed Kathrein: Reed Kathrein is a partner at Hagens Berman, leading the firm's investigation into ImmunityBio's alleged misleading statements.
Apr 02, 2026 · 132 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Reed Kathrein interact across events, view sentiment trends, and discover connected entities.
Open Dashboard